Get started
Work

Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs

Year: 2026
Type: article
Abstract: Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.
DOI: 10.3389/fpubh.2026.1822376
Authors: Marco Schito, Stacey Coe, Jaime Seltzer, Hannah E. Davis, Vidula Sukhatme, Theodore W. Johnson II, Judy Stone, Alexander D. Truong, Linda N. Geng, Tiffany A. Walker
Institutions: Critical Path Institute, Stanford Medicine, Action Network, Stanford University, Patient-Led Research Collaborative, Emory University
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7214936642
FWCI:
Cites: 11
Cited by:
Related to: 10